Transcode Therapeutics (RNAZ) Change in Accured Expenses (2020 - 2026)

Transcode Therapeutics (RNAZ) has 7 years of Change in Accured Expenses data on file, last reported at $1.8 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 993.93% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 1431.78% YoY) and the FY2025 annual result came in at $216541.0, up 163.11% from the prior year.
• Change in Accured Expenses advanced to $1.8 million in Q1 2026, from -$43150.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.0 million in Q3 2022 to a low of -$2.1 million in Q4 2023.
• A 5-year average of $129129.2 and a median of -$43150.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 2145.77% — and 2026, when it surged 993.93%.
• Tracing RNAZ's Change in Accured Expenses over 5 years: stood at $609452.0 in 2022, then tumbled by 442.55% to -$2.1 million in 2023, then surged by 127.62% to $576677.0 in 2024, then tumbled by 107.48% to -$43150.0 in 2025, then jumped by 4211.44% to $1.8 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.8 million (Q1 2026), -$43150.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.